On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
2 mg Pen of Supply-Crippled Ozempic, 3rd Avastin Biosimilar Get Japan Listing
To read the full story
Related Article
- Taisho’s Lusefi OD Film Now Available in Japan
June 20, 2022
- Vabysmo, Ondexxya, Ozempic 2 mg Pen Now Available in Japan
May 26, 2022
- Sandoz to Exclusively Sell Nichi-Iko’s Avastin Biosimilar in Japan
March 31, 2022
- Novo Prepping for Listing of Ozempic 2 mg Version amid Supply Curbs
February 22, 2022
- Lusefi OD Film Approved in Japan: Taisho
February 10, 2022
- Takeda Grabs Approval for Zejula Tablet Form
September 6, 2021
REGULATORY
- Japan Govt Sued for Lack of Information on COVID Vaccine Risks
April 18, 2024
- MOF Ramps Up Push for Use of Cost-Effectiveness Assessment in Reimbursement Decisions
April 17, 2024
- PMDA Stepping Up Generic Compliance Inspections from August Approvals
April 16, 2024
- 14 Makers Picked for Health Minister-Championed Subsidy Program for Cough Meds, Essential Drugs
April 15, 2024
- Japan to Discuss Orphan Designation for Cannabidiol, 2 More Drugs
April 15, 2024
Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…